These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 12239227)

  • 21. Prevalence and molecular genetics of macrolide resistance among Streptococcus pneumoniae isolates collected in Finland in 2002.
    Rantala M; Huikko S; Huovinen P; Jalava J
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4180-4. PubMed ID: 16189096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased activity of 16-membered lactone ring macrolides against erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae: characterization of South African isolates.
    Klugman KP; Capper T; Widdowson CA; Koornhof HJ; Moser W
    J Antimicrob Chemother; 1998 Dec; 42(6):729-34. PubMed ID: 10052895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01.
    Doern GV; Brown SD
    J Infect; 2004 Jan; 48(1):56-65. PubMed ID: 14667792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance.
    Farrell DJ; Jenkins SG; Brown SD; Patel M; Lavin BS; Klugman KP
    Emerg Infect Dis; 2005 Jun; 11(6):851-8. PubMed ID: 15963279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.
    Brown SD; Rybak MJ
    J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i7-15. PubMed ID: 15265831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance.
    Farrell DJ; Morrissey I; Bakker S; Morris L; Buckridge S; Felmingham D
    J Clin Microbiol; 2004 Feb; 42(2):764-8. PubMed ID: 14766850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Streptococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain: in vitro activities of telithromycin and cethromycin.
    Morosini MI; Cantón R; Loza E; del Campo R; Almaraz F; Baquero F
    J Antimicrob Chemother; 2003 Jul; 52(1):50-5. PubMed ID: 12805254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular analysis of Streptococcus pyogenes macrolide resistance of paediatric isolates during a 7 year period (2007-13).
    Michos A; Koutouzi FI; Tsakris A; Chatzichristou P; Koutouzis EI; Daikos GL; Stathi A; Syriopoulou VP
    J Antimicrob Chemother; 2016 Aug; 71(8):2113-7. PubMed ID: 27118782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular characterisation of macrolide resistance mechanisms of Streptococcus pneumoniae and Streptococcus pyogenes isolated in Germany, 2002-2003.
    Reinert RR; Franken C; van der Linden M; Lütticken R; Cil M; Al-Lahham A
    Int J Antimicrob Agents; 2004 Jul; 24(1):43-7. PubMed ID: 15225860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution and molecular characterization of macrolide-resistant Streptococcus pneumoniae in Canada between 1998 and 2008.
    Wierzbowski AK; Karlowsky JA; Adam HJ; Nichol KA; Hoban DJ; Zhanel GG;
    J Antimicrob Chemother; 2014 Jan; 69(1):59-66. PubMed ID: 23970485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. mef(A), mef(E) and a new mef allele in macrolide-resistant Streptococcus spp. isolates from Norway.
    Sangvik M; Littauer P; Simonsen GS; Sundsfjord A; Dahl KH
    J Antimicrob Chemother; 2005 Nov; 56(5):841-6. PubMed ID: 16172106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F; Carnegy F; Willcock J; Amyes S
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distribution of macrolide resistance genes erm(B) and mef(A) among 160 penicillin-intermediate clinical isolates of Streptococcus pneumoniae isolated in southern France.
    Marchandin H; Jean-Pierre H; Jumas-Bilak E; Isson L; Drouillard B; Darbas H; Carrière C
    Pathol Biol (Paris); 2001 Sep; 49(7):522-7. PubMed ID: 11642013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Macrolide-resistance mechanisms in Streptococcus pneumoniae isolates from Belgium.
    Van Eldere J; Meekers E; Lagrou K; Massonet C; Canu A; Devenyns I; Verhaegen J; Syrogiannopoulos G; Leclercq R
    Clin Microbiol Infect; 2005 Apr; 11(4):332-4. PubMed ID: 15760433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PROTEKT 1999-2000: a multicentre study of the antimicrobial susceptibility of respiratory tract pathogens in Japan.
    Inoue M; Kohno S; Kaku M; Yamaguchi K; Igari J; Yamanaka K
    Int J Infect Dis; 2005 Jan; 9(1):27-36. PubMed ID: 15603993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genotypes of macrolide-resistant pneumococci from children in southwestern Japan: raised incidence of strains that have both erm(B) and mef(A) with serotype 6B clones.
    Ikenaga M; Kosowska-Shick K; Gotoh K; Hidaka H; Koga H; Masunaga K; Nagai K; Tsumura N; Appelbaum PC; Matsuishi T
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):16-22. PubMed ID: 18068325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations.
    Zhanel GG; Johanson C; Hisanaga T; Mendoza C; Laing N; Noreddin A; Wierzbowski A; Hoban DJ
    J Antimicrob Chemother; 2004 Dec; 54(6):1072-7. PubMed ID: 15531596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Macrolide Resistance in
    Schroeder MR; Stephens DS
    Front Cell Infect Microbiol; 2016; 6():98. PubMed ID: 27709102
    [No Abstract]   [Full Text] [Related]  

  • 39. Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study.
    Farrell DJ; File TM; Jenkins SG
    J Clin Microbiol; 2007 Feb; 45(2):290-3. PubMed ID: 17093012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
    McGhee P; Clark C; Kosowska-Shick KM; Nagai K; Dewasse B; Beachel L; Appelbaum PC
    Antimicrob Agents Chemother; 2010 Jan; 54(1):230-8. PubMed ID: 19884376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.